Eintrag weiter verarbeiten
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer
Gespeichert in:
| Veröffentlicht in: | Journal of medical genetics 53(2016), 7, Seite 465-471 |
|---|---|
| Personen und Körperschaften: | , , , |
| Titel: | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer/ Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt, Eric Hahnen, Jan Hauke, Britta Bluemcke, Verena Zarghooni, Natalie Herold, Nina Ditsch, Marion Kiechle, Michael Braun, Christine Fischer, Nicola Dikow, Sarah Schott, Nils Rahner, Dieter Niederacher, Tanja Fehm, Andrea Gehrig, Clemens Mueller-Reible, Norbert Arnold, Nicolai Maass, Guntram Borck, Nikolaus de Gregorio, Caroline Scholz, Bernd Auber, Raymonda Varon-Manteeva, Dorothee Speiser, Judit Horvath, Nadine Lichey, Pauline Wimberger, Sylvia Stark, Ulrike Faust, Bernhard H. F. Weber, Gunter Emons, Silke Zachariae, Alfons Meindl, Rita K. Schmutzler, Christoph Engel, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) |
| Format: | E-Book-Kapitel |
| Sprache: | Englisch |
| veröffentlicht: |
29 February 2016
|
| Gesamtaufnahme: |
: Journal of medical genetics, 53(2016), 7, Seite 465-471
, volume:53 |
| Schlagwörter: | |
| Quelle: | Verbunddaten SWB Lizenzfreie Online-Ressourcen |
| LEADER | 04540caa a2200577 4500 | ||
|---|---|---|---|
| 001 | 0-1570920060 | ||
| 003 | DE-627 | ||
| 005 | 20220814091649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180312s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jmedgenet-2015-103672 |2 doi | |
| 035 | |a (DE-627)1570920060 | ||
| 035 | |a (DE-576)500920060 | ||
| 035 | |a (DE-599)BSZ500920060 | ||
| 035 | |a (OCoLC)1340994167 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kast, Karin |d 1971- |e VerfasserIn |0 (DE-588)121172848 |0 (DE-627)705278921 |0 (DE-576)292569157 |4 aut | |
| 245 | 1 | 0 | |a Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer |c Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt, Eric Hahnen, Jan Hauke, Britta Bluemcke, Verena Zarghooni, Natalie Herold, Nina Ditsch, Marion Kiechle, Michael Braun, Christine Fischer, Nicola Dikow, Sarah Schott, Nils Rahner, Dieter Niederacher, Tanja Fehm, Andrea Gehrig, Clemens Mueller-Reible, Norbert Arnold, Nicolai Maass, Guntram Borck, Nikolaus de Gregorio, Caroline Scholz, Bernd Auber, Raymonda Varon-Manteeva, Dorothee Speiser, Judit Horvath, Nadine Lichey, Pauline Wimberger, Sylvia Stark, Ulrike Faust, Bernhard H. F. Weber, Gunter Emons, Silke Zachariae, Alfons Meindl, Rita K. Schmutzler, Christoph Engel, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) |
| 264 | 1 | |c 29 February 2016 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.03.2018 | ||
| 520 | |a Purpose To characterise the prevalence of pathogenic germline mutations in BRCA1 and BRCA2 in families with breast cancer (BC) and ovarian cancer (OC) history. Patients and methods Data from 21 401 families were gathered between 1996 and 2014 in a clinical setting in the German Consortium for Hereditary Breast and Ovarian Cancer, comprising full pedigrees with cancer status of all individual members at the time of first counselling, and BRCA1/2 mutation status of the index patient. Results The overall BRCA1/2 mutation prevalence was 24.0% (95% CI 23.4% to 24.6%). Highest mutation frequencies were observed in families with at least two OCs (41.9%, 95% CI 36.1% to 48.0%) and families with at least one breast and one OC (41.6%, 95% CI 40.3% to 43.0%), followed by male BC with at least one female BC or OC (35.8%; 95% CI 32.2% to 39.6%). In families with a single case of early BC (<36 years), mutations were found in 13.7% (95% CI 11.9% to 15.7%). Postmenopausal unilateral or bilateral BC did not increase the probability of mutation detection. Occurrence of premenopausal BC and OC in the same woman led to higher mutation frequencies compared with the occurrence of these two cancers in different individuals (49.0%; 95% CI 41.0% to 57.0% vs 31.5%; 95% CI 28.0% to 35.2%). Conclusions Our data provide guidance for healthcare professionals and decision-makers to identify individuals who should undergo genetic testing for hereditary breast and ovarian cancer. Moreover, it supports informed decision-making of counselees on the uptake of genetic testing. | ||
| 650 | 4 | |a BRCA1 | |
| 650 | 4 | |a BRCA2 | |
| 650 | 4 | |a Mutation prevalences | |
| 650 | 4 | |a risk criteria | |
| 700 | 1 | |a Fischer, Christine |d 1955- |e VerfasserIn |0 (DE-588)128461993 |0 (DE-627)373010362 |0 (DE-576)297159674 |4 aut | |
| 700 | 1 | |a Dikow, Nicola |e VerfasserIn |0 (DE-588)1073294196 |0 (DE-627)82881726X |0 (DE-576)434859397 |4 aut | |
| 700 | 1 | |a Schott, Sarah |d 1981- |e VerfasserIn |0 (DE-588)133730816 |0 (DE-627)552697281 |0 (DE-576)27460678X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical genetics |d London : BMJ Publishing Group, 1964 |g 53(2016), 7, Seite 465-471 |h Online-Ressource |w (DE-627)319102661 |w (DE-600)2009590-9 |w (DE-576)091210003 |x 1468-6244 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2016 |g number:7 |g pages:465-471 |g extent:7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/jmedgenet-2015-103672 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://jmg.bmj.com/content/53/7/465 |x Verlag |z kostenfrei |3 Volltext |
| 936 | u | w | |d 53 |j 2016 |e 7 |h 465-471 |g 7 |
| 951 | |a AR | ||
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/jmedgenet-2015-103672 |9 LFER |
| 852 | |a LFER |z 2018-04-10T00:00:00Z | ||
| 970 | |c OD | ||
| 971 | |c EBOOK | ||
| 972 | |c EBOOK | ||
| 973 | |c Aufsatz | ||
| 935 | |a lfer | ||
| 900 | |a Fischer, C. | ||
| 900 | |a Schott, Sarah Julia | ||
| 900 | |a Schott, S. | ||
| 951 | |b XA-DE | ||
| 980 | |a 1570920060 |b 0 |k 1570920060 |o 500920060 |c lfer | ||
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Prevalence+of+BRCA1%2F2+germline+mutations+in+21+401+families+with+breast+and+ovarian+cancer&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rft.creator=Kast%2C+Karin&rft.pub=&rft.format=Journal&rft.language=English&rft.issn=1468-6244 |
|---|
| _version_ | 1757949366663905280 |
|---|---|
| access_facet | Electronic Resources |
| author | Kast, Karin, Fischer, Christine, Dikow, Nicola, Schott, Sarah |
| author_facet | Kast, Karin, Fischer, Christine, Dikow, Nicola, Schott, Sarah |
| author_role | aut, aut, aut, aut |
| author_sort | Kast, Karin 1971- |
| author_variant | k k kk, c f cf, n d nd, s s ss |
| callnumber-sort | |
| collection | lfer |
| container_reference | 53(2016), 7, Seite 465-471 |
| container_title | Journal of medical genetics |
| contents | Purpose To characterise the prevalence of pathogenic germline mutations in BRCA1 and BRCA2 in families with breast cancer (BC) and ovarian cancer (OC) history. Patients and methods Data from 21 401 families were gathered between 1996 and 2014 in a clinical setting in the German Consortium for Hereditary Breast and Ovarian Cancer, comprising full pedigrees with cancer status of all individual members at the time of first counselling, and BRCA1/2 mutation status of the index patient. Results The overall BRCA1/2 mutation prevalence was 24.0% (95% CI 23.4% to 24.6%). Highest mutation frequencies were observed in families with at least two OCs (41.9%, 95% CI 36.1% to 48.0%) and families with at least one breast and one OC (41.6%, 95% CI 40.3% to 43.0%), followed by male BC with at least one female BC or OC (35.8%; 95% CI 32.2% to 39.6%). In families with a single case of early BC (<36 years), mutations were found in 13.7% (95% CI 11.9% to 15.7%). Postmenopausal unilateral or bilateral BC did not increase the probability of mutation detection. Occurrence of premenopausal BC and OC in the same woman led to higher mutation frequencies compared with the occurrence of these two cancers in different individuals (49.0%; 95% CI 41.0% to 57.0% vs 31.5%; 95% CI 28.0% to 35.2%). Conclusions Our data provide guidance for healthcare professionals and decision-makers to identify individuals who should undergo genetic testing for hereditary breast and ovarian cancer. Moreover, it supports informed decision-making of counselees on the uptake of genetic testing. |
| ctrlnum | (DE-627)1570920060, (DE-576)500920060, (DE-599)BSZ500920060, (OCoLC)1340994167 |
| doi_str_mv | 10.1136/jmedgenet-2015-103672 |
| facet_avail | Online, Free |
| finc_class_facet | not assigned |
| finc_id_str | 0021032473 |
| footnote | Gesehen am 12.03.2018 |
| format | ElectronicBookComponentPart |
| format_access_txtF_mv | Article, E-Article |
| format_de105 | Ebook |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_del152 | Buch |
| format_detail_txtF_mv | text-online-monograph-child |
| format_dezi4 | e-Book |
| format_finc | Article, E-Article |
| format_legacy | ElectronicBookPart |
| format_strict_txtF_mv | E-Article |
| geogr_code | not assigned |
| geogr_code_person | Germany |
| hierarchy_parent_id | 0-319102661 |
| hierarchy_parent_title | Journal of medical genetics |
| hierarchy_sequence | 53(2016), 7, Seite 465-471 |
| hierarchy_top_id | 0-319102661 |
| hierarchy_top_title | Journal of medical genetics |
| id | 0-1570920060 |
| illustrated | Not Illustrated |
| imprint | 29 February 2016 |
| imprint_str_mv | 29 February 2016 |
| institution | DE-D117, DE-105, LFER, DE-Ch1, DE-15, DE-14, DE-Zwi2 |
| is_hierarchy_id | 0-1570920060 |
| is_hierarchy_title | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer |
| isil_str_mv | LFER |
| issn | 1468-6244 |
| kxp_id_str | 1570920060 |
| language | English |
| last_indexed | 2023-02-16T01:32:40.464Z |
| local_heading_facet_dezwi2 | BRCA1, BRCA2, Mutation prevalences, risk criteria |
| marc024a_ct_mv | 10.1136/jmedgenet-2015-103672 |
| match_str | kast2016prevalenceofbrca12germlinemutationsin21401familieswithbreastandovariancancer |
| mega_collection | Verbunddaten SWB, Lizenzfreie Online-Ressourcen |
| misc_de105 | EBOOK |
| multipart_link | 091210003 |
| multipart_part | (091210003)53(2016), 7, Seite 465-471 |
| names_id_str_mv | (DE-588)121172848, (DE-627)705278921, (DE-576)292569157, (DE-588)128461993, (DE-627)373010362, (DE-576)297159674, (DE-588)1073294196, (DE-627)82881726X, (DE-576)434859397, (DE-588)133730816, (DE-627)552697281, (DE-576)27460678X |
| oclc_num | 1340994167 |
| physical | 7 |
| publishDate | 29 February 2016 |
| publishDateSort | 2016 |
| publishPlace | |
| publisher | |
| record_format | marcfinc |
| record_id | 500920060 |
| recordtype | marcfinc |
| rvk_facet | No subject assigned |
| source_id | 0 |
| spelling | Kast, Karin 1971- VerfasserIn (DE-588)121172848 (DE-627)705278921 (DE-576)292569157 aut, Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt, Eric Hahnen, Jan Hauke, Britta Bluemcke, Verena Zarghooni, Natalie Herold, Nina Ditsch, Marion Kiechle, Michael Braun, Christine Fischer, Nicola Dikow, Sarah Schott, Nils Rahner, Dieter Niederacher, Tanja Fehm, Andrea Gehrig, Clemens Mueller-Reible, Norbert Arnold, Nicolai Maass, Guntram Borck, Nikolaus de Gregorio, Caroline Scholz, Bernd Auber, Raymonda Varon-Manteeva, Dorothee Speiser, Judit Horvath, Nadine Lichey, Pauline Wimberger, Sylvia Stark, Ulrike Faust, Bernhard H. F. Weber, Gunter Emons, Silke Zachariae, Alfons Meindl, Rita K. Schmutzler, Christoph Engel, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC), 29 February 2016, 7, Text txt rdacontent, Computermedien c rdamedia, Online-Ressource cr rdacarrier, Gesehen am 12.03.2018, Purpose To characterise the prevalence of pathogenic germline mutations in BRCA1 and BRCA2 in families with breast cancer (BC) and ovarian cancer (OC) history. Patients and methods Data from 21 401 families were gathered between 1996 and 2014 in a clinical setting in the German Consortium for Hereditary Breast and Ovarian Cancer, comprising full pedigrees with cancer status of all individual members at the time of first counselling, and BRCA1/2 mutation status of the index patient. Results The overall BRCA1/2 mutation prevalence was 24.0% (95% CI 23.4% to 24.6%). Highest mutation frequencies were observed in families with at least two OCs (41.9%, 95% CI 36.1% to 48.0%) and families with at least one breast and one OC (41.6%, 95% CI 40.3% to 43.0%), followed by male BC with at least one female BC or OC (35.8%; 95% CI 32.2% to 39.6%). In families with a single case of early BC (<36 years), mutations were found in 13.7% (95% CI 11.9% to 15.7%). Postmenopausal unilateral or bilateral BC did not increase the probability of mutation detection. Occurrence of premenopausal BC and OC in the same woman led to higher mutation frequencies compared with the occurrence of these two cancers in different individuals (49.0%; 95% CI 41.0% to 57.0% vs 31.5%; 95% CI 28.0% to 35.2%). Conclusions Our data provide guidance for healthcare professionals and decision-makers to identify individuals who should undergo genetic testing for hereditary breast and ovarian cancer. Moreover, it supports informed decision-making of counselees on the uptake of genetic testing., BRCA1, BRCA2, Mutation prevalences, risk criteria, Fischer, Christine 1955- VerfasserIn (DE-588)128461993 (DE-627)373010362 (DE-576)297159674 aut, Dikow, Nicola VerfasserIn (DE-588)1073294196 (DE-627)82881726X (DE-576)434859397 aut, Schott, Sarah 1981- VerfasserIn (DE-588)133730816 (DE-627)552697281 (DE-576)27460678X aut, Enthalten in Journal of medical genetics London : BMJ Publishing Group, 1964 53(2016), 7, Seite 465-471 Online-Ressource (DE-627)319102661 (DE-600)2009590-9 (DE-576)091210003 1468-6244 nnns, volume:53 year:2016 number:7 pages:465-471 extent:7, http://dx.doi.org/10.1136/jmedgenet-2015-103672 Verlag Resolving-System kostenfrei Volltext, http://jmg.bmj.com/content/53/7/465 Verlag kostenfrei Volltext, http://dx.doi.org/10.1136/jmedgenet-2015-103672 LFER, LFER 2018-04-10T00:00:00Z |
| spellingShingle | Kast, Karin, Fischer, Christine, Dikow, Nicola, Schott, Sarah, Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer, Purpose To characterise the prevalence of pathogenic germline mutations in BRCA1 and BRCA2 in families with breast cancer (BC) and ovarian cancer (OC) history. Patients and methods Data from 21 401 families were gathered between 1996 and 2014 in a clinical setting in the German Consortium for Hereditary Breast and Ovarian Cancer, comprising full pedigrees with cancer status of all individual members at the time of first counselling, and BRCA1/2 mutation status of the index patient. Results The overall BRCA1/2 mutation prevalence was 24.0% (95% CI 23.4% to 24.6%). Highest mutation frequencies were observed in families with at least two OCs (41.9%, 95% CI 36.1% to 48.0%) and families with at least one breast and one OC (41.6%, 95% CI 40.3% to 43.0%), followed by male BC with at least one female BC or OC (35.8%; 95% CI 32.2% to 39.6%). In families with a single case of early BC (<36 years), mutations were found in 13.7% (95% CI 11.9% to 15.7%). Postmenopausal unilateral or bilateral BC did not increase the probability of mutation detection. Occurrence of premenopausal BC and OC in the same woman led to higher mutation frequencies compared with the occurrence of these two cancers in different individuals (49.0%; 95% CI 41.0% to 57.0% vs 31.5%; 95% CI 28.0% to 35.2%). Conclusions Our data provide guidance for healthcare professionals and decision-makers to identify individuals who should undergo genetic testing for hereditary breast and ovarian cancer. Moreover, it supports informed decision-making of counselees on the uptake of genetic testing., BRCA1, BRCA2, Mutation prevalences, risk criteria |
| swb_id_str | 500920060 |
| title | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer |
| title_auth | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer |
| title_full | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt, Eric Hahnen, Jan Hauke, Britta Bluemcke, Verena Zarghooni, Natalie Herold, Nina Ditsch, Marion Kiechle, Michael Braun, Christine Fischer, Nicola Dikow, Sarah Schott, Nils Rahner, Dieter Niederacher, Tanja Fehm, Andrea Gehrig, Clemens Mueller-Reible, Norbert Arnold, Nicolai Maass, Guntram Borck, Nikolaus de Gregorio, Caroline Scholz, Bernd Auber, Raymonda Varon-Manteeva, Dorothee Speiser, Judit Horvath, Nadine Lichey, Pauline Wimberger, Sylvia Stark, Ulrike Faust, Bernhard H. F. Weber, Gunter Emons, Silke Zachariae, Alfons Meindl, Rita K. Schmutzler, Christoph Engel, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) |
| title_fullStr | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt, Eric Hahnen, Jan Hauke, Britta Bluemcke, Verena Zarghooni, Natalie Herold, Nina Ditsch, Marion Kiechle, Michael Braun, Christine Fischer, Nicola Dikow, Sarah Schott, Nils Rahner, Dieter Niederacher, Tanja Fehm, Andrea Gehrig, Clemens Mueller-Reible, Norbert Arnold, Nicolai Maass, Guntram Borck, Nikolaus de Gregorio, Caroline Scholz, Bernd Auber, Raymonda Varon-Manteeva, Dorothee Speiser, Judit Horvath, Nadine Lichey, Pauline Wimberger, Sylvia Stark, Ulrike Faust, Bernhard H. F. Weber, Gunter Emons, Silke Zachariae, Alfons Meindl, Rita K. Schmutzler, Christoph Engel, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) |
| title_full_unstemmed | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt, Eric Hahnen, Jan Hauke, Britta Bluemcke, Verena Zarghooni, Natalie Herold, Nina Ditsch, Marion Kiechle, Michael Braun, Christine Fischer, Nicola Dikow, Sarah Schott, Nils Rahner, Dieter Niederacher, Tanja Fehm, Andrea Gehrig, Clemens Mueller-Reible, Norbert Arnold, Nicolai Maass, Guntram Borck, Nikolaus de Gregorio, Caroline Scholz, Bernd Auber, Raymonda Varon-Manteeva, Dorothee Speiser, Judit Horvath, Nadine Lichey, Pauline Wimberger, Sylvia Stark, Ulrike Faust, Bernhard H. F. Weber, Gunter Emons, Silke Zachariae, Alfons Meindl, Rita K. Schmutzler, Christoph Engel, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) |
| title_in_hierarchy | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer / Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt, Eric Hahnen, Jan Hauke, Britta Bluemcke, Verena Zarghooni, Natalie Herold, Nina Ditsch, Marion Kiechle, Michael Braun, Christine Fischer, Nicola Dikow, Sarah Schott, Nils Rahner, Dieter Niederacher, Tanja Fehm, Andrea Gehrig, Clemens Mueller-Reible, Norbert Arnold, Nicolai Maass, Guntram Borck, Nikolaus de Gregorio, Caroline Scholz, Bernd Auber, Raymonda Varon-Manteeva, Dorothee Speiser, Judit Horvath, Nadine Lichey, Pauline Wimberger, Sylvia Stark, Ulrike Faust, Bernhard H. F. Weber, Gunter Emons, Silke Zachariae, Alfons Meindl, Rita K. Schmutzler, Christoph Engel, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC), |
| title_short | Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer |
| title_sort | prevalence of brca1 2 germline mutations in 21 401 families with breast and ovarian cancer |
| topic | BRCA1, BRCA2, Mutation prevalences, risk criteria |
| topic_facet | BRCA1, BRCA2, Mutation prevalences, risk criteria |
| url | http://dx.doi.org/10.1136/jmedgenet-2015-103672, http://jmg.bmj.com/content/53/7/465 |